Drug-induced corneal complications

Current Opinion in Ophthalmology

Volumn 15, Issue 6, 2004, Pages 541-548

  Hollander, David A ^a   Aldave, Anthony J ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

Author keywords

Corneal deposition; Corneal toxicity; Crystalline keratopathy; Drug toxicity; Keratopathy; Ocular toxicity; Stromal deposition; Systemic medication; Vortex keratopathy

Indexed keywords

AMIODARONE; AMODIAQUINE; ATOVAQUONE; CHLOROQUINE; CLOFAZIMINE; CYTARABINE; GENTAMICIN; GOLD; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOGLOBULIN; INDOMETACIN; ISOTRETINOIN; MEPACRINE; MONOBENZONE; NAPROXEN; PERHEXILINE; PHENOTHIAZINE; RETINOID; SILVER; SURAMIN; TAMOXIFEN; TILORONE;

AQUEOUS HUMOR; BASEMENT MEMBRANE; CLINICAL FEATURE; CORNEA; CORNEA DEPOSITION; CORNEA DISEASE; CORNEA LIMBUS; CRYSTALLINE KERATOPATHY; CYST; DOSE RESPONSE; DRUG TOXICITY; EPITHELIAL MICROCYST; EPITHELIUM CELL; EYE IRRITATION; EYE TOXICITY; HUMAN; KERATOPATHY; LIPIDOSIS; PHOTOPHOBIA; PRIORITY JOURNAL; REVIEW; SLIT LAMP; STROMA; STROMA DEPOSITION; SYSTEMIC THERAPY; TEAR FILM; TREATMENT WITHDRAWAL; VISUAL DISORDER; VORTEX KERATOPATHY;

CORNEAL DISEASES; CORNEAL STROMA; ENDOTHELIUM, CORNEAL; EPITHELIUM, CORNEAL; HUMANS; VISUAL ACUITY;

EID: 9444220777     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icu.0000143688.45232.15     Document Type: Review

References (83)

1. D'Amico DJ, Kenyon KR: Drug-induced lipidoses of the cornea and conjunctiva, Int Ophthalmol 1981, 4:67-76.
2. Francois J: Cornea verticillata. Bull Soc Belge Ophtalmol 1968, 150:656-670.
3. Lullmann H, Lullmann-Rauch R, Wassermann O: Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Grit Rev Toxicol 1975, 4:185-218.
4. Dua HS, Singh A, Gomes JA, et al.: Vortex or whorl formation of cultured human corneal epithelial cells induced by magnetic fields. Eye 1996, 10:447-450.
5. Ingram DV, Jaggarao NS, Chamberlain DA: Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol 1982, 66:676-679.
6. Kaplan LJ, Cappaert WE: Amiodarone keratopathy. Correlation to dosage and duration. Arch Ophthalmol 1982, 100:601-602.
7. Greene HL, Graham EL, Werner JA, et al.: Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 1983, 2:1114-1128.
8. Harris L, McKenna WJ, Rowland E, Krikler DM: Side effects and possible contraindications of amiodarone use. Am Heart J 1983, 106:916-923.
9. Orlando RG, Dangel ME, Schaal SF: Clinical experience and grading of amiodarone keratopathy. Ophthalmology 1984, 91:1184-1187.
10. Dolan BJ, Flach AJ, Peterson JS: Amiodarone keratopathy and lens opacities. J Am Optom Assoc 1985, 56:468-470.
11. Ikaheimo K, Kettunen R, Mantyjarvi M: Visual functions and adverse ocular effects in patients with amiodarone medication. Acta Ophthalmol Scand 2002, 80:59-63.
12. D'Amico DJ, Kenyon KR, Ruskin JN: Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol 1981, 99:257-261.
13. Haug SJ, Friedman AH: Identification of amiodarone in corneal deposits. Am J Ophthalmol 1991, 111:518-520.
14. Mantyjarvi M, Tuppurainen K, Ikaheimo K: Ocular side effects of amiodarone, Surv Ophthalmol 1998, 42:360-366.
15. Ciancaglini M, Carpineto P, Zuppardi E, et al.: In vivo confocal microscopy of patients with amiodarone-induced keratopathy. Cornea 2001, 20:368-373.
16. Rivera RP, Younge BR, Dyer JA: Atypical amiodarone-induced keratopathy in a patient wearing soft contact lenses. CLAO J 1989, 15:219-221.
17. Rogers NK, Bowen DI, Noble BA: Development of atypical amiodarone keratopathy in a corneal graft. Eye 1993, 7:594-596.
18. Davitt SP, Mannis MJ: Delayed development of amiodarone keratopathy in a corneal graft. Cornea 1997, 16:695-697.
19. Thystrup JD, Fledelius HC: Retinal maculopathy possibly associated with amiodarone medication. Acta Ophthalmol (Copenh) 1994, 72:639-641.
20. Feiner LA, Younge BR, Kazmier FJ, et al.: Optic neuropathy and amiodarone therapy. Mayo Clin Proc 1987, 62:702-717.
21. Bernstein HN: Chloroquine ocular toxicity. Surv Ophthalmol 1967, 12:415-447.
22. Shearer RV, Dubois EL: Ocular changes induced by long-term hydroxychloroquine (plaquenil) therapy. Am J Ophthalmol 1967, 64:245-252.
23. Hirst LW, Sanborn G, Green WR, et al.: Amodiaquine ocular changes. Arch Ophthalmol 1982, 100:1300-1304.
24. Pulhorn G, Thiel HJ: Ultrastructural aspects of chloroquine-keratopathy. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1976, 201:89-99.
25. Easterbrook M: Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol 1990, 25:249-251.
26. Grierson DJ: Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 1997, 56:188-190.
27. Jeddi A, Ben Osman N, Daghfous F, et al.: The cornea and synthetic antimalarials. J Fr Ophtalmol 1994, 17:36-38.
28. Neubauer AS, Samari-Kermani K, Schaller U, et al.: Detecting chloroquine retinopathy: electro-oculogram versus colour vision. Br J Ophthalmol 2003, 87:902-908. A detailed screening of 93 patients on chloroquine and hydroxychloroquine for retinopathy, using electro-oculogram and computerized color vision testing, which demonstrated a positive correlation (50% sensitivity, 90% specificity) of corneal verticillata with advanced retinopathy.
29. Marmor MF, Carr RE, Easterbrook M, et al.: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002, 109:1377-1382.
30. Teich SA, Handwerger S, Mathur-Wagh U, et al.: Toxic keratopathy associated with suramin therapy. N Engl J Med 1986, 314:1455-1456.
31. Holland EJ, Stein CA, Palestine AG, et al.: Suramin keratopathy. Am J Ophthalmol 1988, 106:216-220.
32. Constantopoulos G, Rees S, Cragg BG, et al.: Effect of suramin on the activities of degradative enzymes of sphingolipids in rats. Res Commun Chem Pathol Pharmacol 1981, 32:87-97.
33. Kaiser-Kupfer MI, Lippman ME: Tamoxifen retinopathy. Cancer Treat Rep 1978, 62:315-320.
34. McKeown CA, Swartz M, Blom J, Maggiano JM: Tamoxifen retinopathy. Br J Ophthalmol 1981, 65:177-179.
35. Pavlidis NA, Petris C, Briassoulis E, et al.: Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992, 69:2961-2964.
36. Heier J, Dragoo R, Enzenauer RW, Waterhouse WJ: Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 1994, 117:772-775.
37. Noureddin BN, Seoud M, Bashshur Z, et al.: Ocular toxicity in low-dose tamoxifen: a prospective study. Eye 1999, 13:729-733.
38. Gibson JM, Fielder AR, Garner A, Millac P: Severe ocular side effects of perhexilene maleate: case report. Br J Ophthalmol 1984, 68:553-560.
39. Shah GK, Cantrill HL, Holland EJ: Vortex keratopathy associated with atovaquone. Am J Ophthalmol 1995, 120:669-671.
40. Johnson AW, Buffaloe WJ: Chlorpromazine epithelial keratopathy. Arch Ophthalmol 1966, 76:664-667.
41. Walinder PE, Gip L, Stempa M: Corneal changes in patients treated with clofazimine. Br J Ophthalmol 1976, 60:526-528.
42. Weiss JN, Weinberg RS, Regelson W: Keratopathy after oral administration of tilorone hydrochloride. Am J Ophthalmol 1980, 89:46-53.
43. Burns CA: Indomethacin, reduced retinal sensitivity, and corneal deposits. Am J Ophthalmol 1968, 66:825-835.
44. Szmyd L Jr, Perry HD: Keratopathy associated with the use of naproxen. Am J Ophthalmol 1985, 99:598.
45. Fitt A, Dayan M, Gillie RF: Vortex keratopathy associated with ibuprofen therapy. Eye 1996, 10:145-146.
46. Hedges TR 3rd, Kenyon KR, Hanninen LA, Mosher DB: Corneal and conjunctival effects of monobenzone in patients with vitiligo. Arch Ophthalmol 1983, 101:64-68.
47. Kaufman HE, Capella JA, Maloney ED, et al.: Corneal toxicity of cytosine arabinoside. Arch Ophthalmol 1964, 72:535-540.
48. Hopen G, Mondino BJ, Johnson BL, Chervenick PA: Corneal toxicity with systemic cytarabine. Am J Ophthalmol 1981, 91:500-504.
49. Lass JH, Lazarus HM, Reed MD, Herzig RH: Topical corticosteroid therapy for corneal toxicity form systemically administered cytarabine. Am J Ophthalmol 1982, 94:617-621.
50. Lazarus HM, Hartnett ME, Reed MD, et al.: Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis. Am J Ophthalmol 1987, 104:476-480.
51. Ritch PS, Hansen RM, Heuer DK: Ocular toxicity from high-dose cytosine arabinoside. Cancer 1983, 51:430-432.
52. DeLong SL, Poley BJ, McFarlane JR Jr: Ocular changes associated with long-term chlorpromazine therapy. Arch Ophthalmol 1965, 73:611-617.
53. Wetterholm DH, Snow HL, Winter FC: A clinical study of pigmentary change in cornea and lens in chronic chlorpromazine therapy. Arch Ophthalmol 1965, 74:55-56.
54. Thaler JS, Curinga R, Kiracofe G: Relation of graded ocular anterior chamber pigmentation to phenothiazine intake in schizophrenics-quantification procedures. Am J Optom Physiol Opt 1985, 62:600-604.
55. Hull DS, Csukas S, Green K: Chlorpromazine-induced corneal endothelial phototoxicity. Invest Ophthalmol Vis Sci 1982, 22:502-508.
56. Deluise VP, Flynn JT: Asymmetric anterior segment changes induced by chlorpromazine. Ann Ophthalmol 1981, 13:953-955.
57. Bernstein HN: Some iatrogenic ocular diseases from systemically administered drugs, Int Ophthalmol Clin 1970, 10:553-619.
58. Webber SK, Domniz Y, Sutton GL, et al.: Corneal deposition after high-dose chlorpromazine hydrochloride therapy. Cornea 2001, 20:217-219.
59. Weekley RD, Potts AM, Reboton J, May RH: Pigmentary retinopathy in patients receiving high doses of a new phenothiazine. Arch Ophthalmol 1960, 64:65-76.
60. Siddall JR: The ocular toxic findings with prolonged and high dosage chlorpromazine intake. Arch Ophthalmol 1965, 74:460-464.
61. Rasmussen K, Kirk L, Faurbye A: Deposits in the lens and cornea of the eye during long-term chlorpromazine medication. Acta Psychiatr Scand 1976, 53:1-6.
62. Davidorf FH: Thioridazine pigmentary retinopathy. Arch Ophthalmol 1973, 90:251-255.
63. Cahane M, Chen V, Avni I: Persistent chlorpromazine deposits in donor corneal tissue after corneal transplantation. Cornea 1997, 16:588-589.
64. Craythorn JM, Swartz M, Creel DJ: Clofazimine-induced bull's-eye retinopathy. Retina 1986, 6:50-52.
65. Kaur I, Ram J, Kumar B, et al.: Effect of clofazimine on eye in multibacillary leprosy. Indian J Lepr 1990, 62:87-90.
66. Ohman L, Wahlberg I: Letter: Ocular side-effects of clofazimine. Lancet 1975, 2:933-934.
67. Font RL, Sobol W, Matoba A: Polychromatic corneal and conjunctival crystals secondary to clofazimine therapy in a leper. Ophthalmology 1989, 96:311-315.
68. Fraunfelder FT, LaBraico JM, Meyer SM: Adverse ocular reactions possibly associated with isoretinoin. Am J Ophthalmol 1985, 100:534-537.
69. Ellies P, Dighiero P, Legeais JM, et al.: Persistent corneal opacity after oral isoretinoin therapy for acne. Cornea 2000, 19:238-239.
70. Hashimoto A, Maeda Y, Ito H, et al.: Corneal chrysiasis. A clinical study in rheumatoid arthritis patients receiving gold therapy. Arthritis Rheum 1972, 15:309-315.
71. McCormick SA, DiBartolomeo AG, Raju VK, Schwab IR: Ocular chrysiasis. Ophthalmology 1985, 92:1432-1435.
72. Kincaid MC, Green WR, Hoover RE, Schenck PH: Ocular chrysiasis. Arch Ophthalmol 1982, 100:1791-1794.
73. Bron AJ, McLendon BF, Camp AV: Epithelial deposition of gold in the cornea in patients receiving systemic therapy. Am J Ophthalmol 1979, 88:354-360.
74. Lopez JD, del Castillo JM, Lopez CD, Sanchez JG: Confocal microscopy in ocular chrysiasis. Cornea 2003, 22:573-575. A case report using confocal microscopy to demonstrate the presence of gold deposition in the mid-stroma of a patient 9 years following drug cessation. The relative scarcity of deposition in the posterior stroma, the typical site for gold deposition, suggests earlier clearance of the deeper layers following drug cessation.
75. Rodenhauser JH: Ocular changes following parenteral gold treatment. Klin Monatsbl Augenheilkd 1969, 155:61-65.
76. Ormerod LD, Collin HB, Dohlman CH, et al.: Paraproteinemic crystalline keratopathy. Ophthalmology 1988, 95:202-212.
77. Budde M, Gusek-Schneider GC, Mayer U, Seitz B: Annular crystalline keratopathy in association with immunoglobulin therapy for pyoderma gangrenosum. Cornea 2003, 22:82-85. A novel case report of crystalline corneal deposition in association with the use of exogenous immunoglobulins, with corneal changes resembling those seen with systemic paraglobulinemias.
78. Osusky R, Morell A, Imbach P, Lerch PG: Diffusion of immunoglobulins into rabbit cornea after subconjunctival injection: experimental demonstration and mathematical model. Graefes Arch Clin Exp Ophthalmol 1993, 231:122-128.
79. Saran BR, Maguire AM, Nichols C, et al.: Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 1994, 112:1159-1165.
80. Bhagat N, Read RW, Rao NA, et al.: Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. Ophthalmology 2001, 108:750-752.
81. Holland SP, Chang CW, Vagh M, Courtright P: Corneal endothelial deposits in patients with HIV infection or AIDS: epidemiologic evidence of the contribution of rifabutin. Can J Ophthalmol 1999, 34:204-209.
82. Smith JA, Mueller BU, Nussenblatt RB, Whitcup SM: Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia. Am J Ophthalmol 1999, 127:164-169.
83. Ponjavic V, Granse L, Bengtsson Stigmar E, Andreasson S: Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin. Acta Ophthalmol Scand 2002, 80:553-556.